Evidence map›Paper›PMID 40330712›Full record

ArticleAdvances in radiation oncology2025

National Institutes of Health Funding to Support Radiation Oncology Research: A Comparative Trend Analysis Over a Decade, 2011-2021.

Amir Razavi, Michael K Rooney, Clifton D Fuller, James B Yu, Neil T Pfister, Charles R Thomas, John M Buatti, Sophia C Kamran, Heather M McGee, Debra Nana Yeboa and 3 more

Abstract read
In one paragraph

Article in Advances in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Amir RazaviDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas.
Michael K RooneyDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas.
Clifton D FullerDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas.
James B YuDepartment of Radiation Oncology, St. Francis Hospital, Hartford, Connecticut.
Neil T PfisterDepartment of Radiation Oncology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama.
Charles R ThomasRadiation Oncology Department, Dartmouth Cancer Center and Geisel School of Medicine, Lebanon, New Hampshire.
John M BuattiDepartment of Radiation Oncology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa.
Sophia C KamranDepartment of Radiation Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Heather M McGeeDepartment of Radiation Oncology and Immuno-Oncology, City of Hope, Duarte, California.
Debra Nana YeboaDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas.
Ana P KiessDepartment of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Andrew M BaschnagelDepartment of Human Oncology, UW Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Randall J KimpleDepartment of Human Oncology, UW Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3M
Investigating the Role of Radiation-induced Cell Death in Innate Lymphoid Cell Activation within Unique Tumor MicroenvironmentsR00CA256526 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI MCGEE, HEATHER MICHELLE · 2022 to 2024
$747k
NCI NIH HHS P30 CA014520NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA023108NCI NIH HHS R00 CA256526
6 · The paper itself

Abstract

Purpose: Funding to support radiation oncology discovery and research is essential for advancement in therapeutic strategies to improve outcomes for patients with cancer. We aimed to comprehensively characterize trends in National Institutes of Health (NIH) funding that supports radiation oncology research over time to identify trends, successes, and areas for improvement. Methods and Materials: We queried the NIH Research Portfolio Online Reporting Tools Expenditures and Results database to identify all awarded grants to support radiation oncology research conducted by principal investigators at academic centers, using 3 individual years as representative samples (2011, 2016, and 2021). Abstracts and keywords for resulting grants were manually searched to identify resulting awards topically related to the field of radiation oncology; principal investigators departmental affiliation was also used as a supplemental method serving as a sensitivity analysis to define radiation oncology-related research. Descriptive statistics were used to describe patterns in funding. χ Results: Less than 0.5% of the total NIH budget and < 2% of the total National Cancer Institute budget supported radiation oncology research during the representative study years. There were no significant changes in this allocation pattern over time. A small cohort of institutions held a relatively large proportion of NIH-supported radiation oncology grant funding. Individuals holding PhDs alone received the majority of funding (62%), whereas those with dual-degrees (MD/PhD) held 21% of funding, and those with MD alone were awarded 17% of funding. There was a trend toward an increased proportion of grants awarded to MD/PhDs over time (24% vs 15% in 2021 and 2011, respectively, Conclusions: Despite radiation therapy's essential role in multidisciplinary cancer care, NIH, and National Cancer Institute funding to support radiation oncology research has remained disproportionally low over the last decade. These data may be useful to inform future policy aimed at promoting research advancement in radiation oncology both at the micro (individual) as well as macro (institutional and national) level.

Identifiers

PMID40330712
PMCPMC12051116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.